Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on a on a novel antibody-drug conjugate (ADC)-linker technology. ADCs deliver for example chemotherapeutic drugs specifically to the tumor and thus enable targeted chemotherapy. The stable and defined linkage of the drug to the antibody is essential for ADC stability, efficacy and mitigation of side effects. With their proprietary linker technology they are able to readily attach any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering and thereby generate highly efficient ADCs. The ease of drug attachment, the favorable stability and versatility of the technology will allow them to generate highly potent agents for various indications with a high safety profile.